Wellington Management Group LLP Sells 5,579 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Wellington Management Group LLP trimmed its position in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 3.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 179,612 shares of the company’s stock after selling 5,579 shares during the period. Wellington Management Group LLP owned 0.18% of Aquestive Therapeutics worth $639,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also bought and sold shares of AQST. New York State Common Retirement Fund lifted its position in shares of Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after acquiring an additional 10,700 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at $44,000. Two Sigma Advisers LP bought a new stake in shares of Aquestive Therapeutics during the 4th quarter valued at $57,000. PKS Advisory Services LLC purchased a new stake in Aquestive Therapeutics during the 4th quarter worth about $63,000. Finally, ProShare Advisors LLC boosted its stake in Aquestive Therapeutics by 79.8% in the 4th quarter. ProShare Advisors LLC now owns 25,232 shares of the company’s stock worth $90,000 after purchasing an additional 11,200 shares during the period. 32.45% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AQST has been the topic of several analyst reports. Alliance Global Partners reiterated a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Raymond James set a $7.00 target price on shares of Aquestive Therapeutics in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research note on Thursday, May 15th. Lake Street Capital reduced their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Finally, Oppenheimer initiated coverage on Aquestive Therapeutics in a research report on Monday, June 2nd. They issued an “outperform” rating and a $7.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $10.14.

Aquestive Therapeutics Price Performance

AQST stock opened at $3.56 on Friday. The firm has a 50 day simple moving average of $2.69 and a two-hundred day simple moving average of $3.13. The stock has a market cap of $353.61 million, a PE ratio of -7.91 and a beta of 1.94. Aquestive Therapeutics, Inc. has a one year low of $2.12 and a one year high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.07). The firm had revenue of $8.72 million for the quarter, compared to the consensus estimate of $12.23 million. On average, research analysts expect that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.